Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug series
|
| gptkbp:clinicalTrialPhase |
gptkb:United_States
|
| gptkbp:developedBy |
NeuroRx, Inc.
|
| https://www.w3.org/2000/01/rdf-schema#label |
NRX series
|
| gptkbp:includes |
NRX-100
NRX-101 |
| gptkbp:NRX-100 |
ketamine formulation
|
| gptkbp:NRX-101 |
combination of D-cycloserine and lurasidone
|
| gptkbp:regulates |
investigational
|
| gptkbp:relatedTo |
psychiatric treatments
|
| gptkbp:usedFor |
treatment-resistant depression
bipolar depression |
| gptkbp:bfsParent |
gptkb:Project_Rover
|
| gptkbp:bfsLayer |
7
|